KDM6B and cancer: The Cancer Therapeutic Response Portal correlated the sensitivity patterns of 481 compounds including GSK-J4 with 19,000 basal transcript levels across 823 different human cancer cell lines and identified selective outlier transcripts44,45, which allowed us to interrogate whether the KDM6B inhibitor activity was correlated with specific transcripts.